Atyr PHARMA (NASDAQ:ATYR) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a report released on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock.

Several other research analysts also recently issued reports on ATYR. Leerink Partners assumed coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target on the stock. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Cantor Fitzgerald initiated coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating for the company. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Atyr PHARMA presently has a consensus rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Trading Down 0.5 %

Shares of ATYR opened at $3.97 on Friday. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average price is $3.65 and its 200-day moving average price is $3.06. The firm has a market capitalization of $333.25 million, a price-to-earnings ratio of -4.22 and a beta of 0.98.

Atyr PHARMA (NASDAQ:ATYR) last released its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Sell-side analysts anticipate that Atyr PHARMA will post -0.91 EPS for the current year.

Hedge Funds Weigh In On Atyr PHARMA

Several hedge funds and other institutional investors have recently modified their holdings of the company. D.A. Davidson & CO. purchased a new stake in Atyr PHARMA during the fourth quarter valued at $141,000. JPMorgan Chase & Co. grew its stake in shares of Atyr PHARMA by 52.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares during the period. Alterna Wealth Management Inc. purchased a new stake in shares of Atyr PHARMA during the 4th quarter valued at about $36,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Atyr PHARMA in the fourth quarter worth approximately $170,000. Finally, American Century Companies Inc. bought a new stake in Atyr PHARMA during the fourth quarter valued at approximately $319,000. 61.72% of the stock is owned by institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.